Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $37.43 million versus the consensus estimate of $44.5 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.